{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import openai\n",
    "import json\n",
    "import pandas as pd\n",
    "from transformers import GPT2TokenizerFast"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "openai authentication"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# openai.organization = \"org-iKrZv1G3h27ngg6tO3rkCDlk\" mine \n",
    "openai.organization = \"org-us16wmNswbfs7htSVY2eiaYh\" # zazu\n",
    "# openai.api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "# openai.api_key = \"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\" mine \n",
    "openai.api_key = \"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\" # zazu"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# text = \"Pre- Study\tCycle 1\tCycle 2\tCycle 3\tCycle 4\tCycle 5\tCycle 6\tTreatment Discontinuation\tOff Study1\tInformed consent\tSELECTED X\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED2\tDemographics\tSELECTED X\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED3\tMedical history\tSELECTED X\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED4\tPhysical exam\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X5\tVital signs\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X6\tHeight\tSELECTED X\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED7\tWeight\tSELECTED X\tNOT_SELECTED\tNOT_SELECTED\tSELECTED X\tNOT_SELECTED\tSELECTED X\tNOT_SELECTED\tSELECTED X\tSELECTED X8\tBiopsy diagnostic of KS (fixed in formalin)\tSELECTED Xe\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED9\tFACT-G Questionnaire\tNOT_SELECTED\tSELECTED Xf\tNOT_SELECTED\tNOT_SELECTED\tSELECTED X\tNOT_SELECTED\tNOT_SELECTED\tSELECTED X\tSELECTED X10\tToxicity evaluations\tNOT_SELECTED\tSELECTED\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X11\tPerformance status\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X12\tCBC w/diff, plts\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED\tSELECTED X\tSELECTED X13\tSerum chemistry\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X14\tOxygen saturation\tSELECTED Xb\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X15\tRadiologic evaluation\tSELECTED X\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tNOT_SELECTED\tSELECTED X\tSELECTED X16\tTumor measurements\tSELECTED X\tNOT_SELECTED\tSELECTED X\tNOT_SELECTED\tSELECTED X\tNOT_SELECTED\tSELECTED X\tSELECTED X\tSELECTED X17\tPregnancy test\tSELECTED Xd\tNOT_SELECTED\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tSELECTED X\tNOT_SELECTED\tNOT_SELECTED\"\n",
    "# text = 'Primary objective: Assess at week 12/16, post biologic treatment, the sensitivity and the specificity, compared to DLQI as a standard tool, of the PSO-TARGET QoL component grid as a novel approach aiming to evaluate the patients’ satisfaction with regard of their treatment.'"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "read in the protocol in csv format and convert to string"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [],
   "source": [
    "# data = pd.read_csv('textract/trial0049/text.csv')\n",
    "data = pd.read_csv('cut_trial0032.csv')\n",
    "text = data.astype(str)"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Clean up chunk data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"['Non-Interventional Study Protocol', 'Study Short Title', 'Evaluation of the sensitivity and specificity of a novel quality of life (QoL)', 'tool to assess the treatment satisfaction in psoriasis patients', 'STUDY IDENTIFICATION No. 2020-A00652-37', 'Full Study Title', 'Evaluation of the sensitivity and specificity, compared to DLQI as a standard tool, of a novel', 'QoL questionnaire (treat to the PSOriasis patient satiSfactiOn TARGET) among moderate to', 'severe psoriasis patients treated with brodalumab (Kyntheum)', 'GPP statement:', 'This Non-Interventional Study will be conducted in compliance with the', 'Clinical Study Protocol, Good Pharmacoepidemiology Practices and', 'applicable regulatory requirement(s)', 'Sponsoring entity:', 'LEO Study ID: PSO-TARGET', 'LEO Pharma France', '2 rue René Caudron', 'Date: 25-05-2020', '215 avenue Georges Clemenceau', '78960 Voisins-Le-Bretonneux', 'Version: 2.0']\""
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text['Text'][0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "text = text.replace({\",\":\"\", \"'\":\"\"}, regex=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'[Non-Interventional Study Protocol Study Short Title Evaluation of the sensitivity and specificity of a novel quality of life (QoL) tool to assess the treatment satisfaction in psoriasis patients STUDY IDENTIFICATION No. 2020-A00652-37 Full Study Title Evaluation of the sensitivity and specificity compared to DLQI as a standard tool of a novel QoL questionnaire (treat to the PSOriasis patient satiSfactiOn TARGET) among moderate to severe psoriasis patients treated with brodalumab (Kyntheum) GPP statement: This Non-Interventional Study will be conducted in compliance with the Clinical Study Protocol Good Pharmacoepidemiology Practices and applicable regulatory requirement(s) Sponsoring entity: LEO Study ID: PSO-TARGET LEO Pharma France 2 rue René Caudron Date: 25-05-2020 215 avenue Georges Clemenceau 78960 Voisins-Le-Bretonneux Version: 2.0]'"
      ]
     },
     "execution_count": 110,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text['Text'][0]"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## check how much it will cost to process"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "tokenizer = GPT2TokenizerFast.from_pretrained(\"gpt2\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Token indices sequence length is longer than the specified maximum sequence length for this model (1101 > 1024). Running this sequence through the model will result in indexing errors\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "22665"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "i = 0\n",
    "tokens = 0\n",
    "cost = 0\n",
    "while i < len(text):\n",
    "    tokens += len(tokenizer(text.iloc[i][2])[0])\n",
    "    # print(len(tokenizer(text.iloc[i][2])[0]))\n",
    "    i += 1\n",
    "tokens"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "cost = tokens / 1000 x 2c <br>\n",
    "cost will be slightly higher because we have to add the question and the answers each time but we can't really know the length of the answer or how many times we will be running the API at this point "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Cost of whole document: €0.453\n"
     ]
    }
   ],
   "source": [
    "cost = tokens / 1000 * 0.02\n",
    "print(f\"Cost of whole document: €{cost:.3f}\")"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Sections "
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Section where questionnaires could be found\n",
    "1. Primary and Secondary endpoints/objectives: page 20\n",
    "2. Exploratory outcomes: none\n",
    "3. Schedule of events table, flow chart: table on page 28\n",
    "5. Assessments: page 29\n",
    "6. Abbreviations: page 7\n",
    "7. Outcomes and questionnaires:none\n",
    "8. Rationale and background: page 10\n",
    "9. Data sources: page 14"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "metadata": {},
   "outputs": [],
   "source": [
    "sections = []\n",
    "pages = [20, 28, 29, 7, 10 , 14]\n",
    "i = 0\n",
    "while i < len(text):\n",
    "    if i in pages:\n",
    "        sections.append(text.iloc[i-1][2])\n",
    "    i += 1\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "for section in sections:\n",
    "    print(section)\n",
    "    print()"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### GPT3 API\n",
    "1. Run the sections\n",
    "2. Extract the answers\n",
    "3. Add answers to list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "metadata": {},
   "outputs": [],
   "source": [
    "section_answers = []\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "metadata": {},
   "outputs": [],
   "source": [
    "for section in sections:\n",
    "    completion = openai.Completion.create(\n",
    "    model=\"text-davinci-003\",\n",
    "    prompt=f\"extract the validated clinical questionnaires used in this text:{section}\",\n",
    "    max_tokens=300,\n",
    "    temperature=0\n",
    "    )\n",
    "    answer = completion[\"choices\"][0][\"text\"]\n",
    "    section_answers.append(answer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "metadata": {},
   "outputs": [],
   "source": [
    "section_answers = ['\\n\\nValidated Clinical Questionnaires:\\n- NIS-PSO-TARGET\\n- DLQI\\n- PASI\\n- PRO\\n- QoL',\n",
    " '\\n\\nNIS-PSO-TARGET QOL questionnaire (treat to the Patient satiSfactiOn TARGET in Psoriasis patients) Dermatology Life Quality Index (DLQI)',\n",
    " '\\n\\nNIS-PSO-TARGET\\nDLQI\\nPSO-TARGET component grid\\nPASI Scores',\n",
    " '\\n\\nNIS-PSO-TARGET, DLQI, PSO-TARGET QoL Component grid, Likert scale, PASI score',\n",
    " '\\n\\nValidated Clinical Questionnaires:\\n- NIS-PSO-TARGET\\n- PASI\\n- QoL component grid\\n- DLQI\\n- PSO-TARGET QoL component grid',\n",
    " '\\n\\nNIS-PSO-TARGET\\nThe Dermatology Quality of Life Index (DLQI)\\nPSO-TARGET QoL component grid']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['\\n\\nValidated Clinical Questionnaires:\\nDLQI, PASI, PRO, QoL',\n",
       " '\\n\\nValidated Clinical Questionnaires:\\nDermatology Life Quality Index (DLQI)',\n",
       " '\\n\\nValidated Clinical Questionnaires used in this text:\\n\\n- PSO-TARGET QoL Component Grid\\n- DLQI\\n- PASI Scores',\n",
       " '\\n\\nValidated clinical questionnaires used in this text:\\n\\n- DLQI (Dermatology Life Quality Index)\\n- PSO-TARGET QoL Component Grid',\n",
       " '\\n\\nValidated clinical questionnaires used in this text:\\n\\n- Psoriasis Area and Severity Index (PASI)\\n- Quality of Life component grid\\n- Dermatology Life Quality Index (DLQI)\\n- Psoriasis Treatment Outcome Target (PSO-TARGET) Quality of Life component grid',\n",
       " '\\n\\nValidated clinical questionnaires used in this text:\\n\\n1. Dermatology Quality of Life Index (DLQI)\\n2. PSO-TARGET QoL component grid']"
      ]
     },
     "execution_count": 131,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "section_answers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 132,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Validated Clinical Questionnaires:DLQI, PASI, PRO, QoL',\n",
       " 'Validated Clinical Questionnaires:Dermatology Life Quality Index (DLQI)',\n",
       " 'Validated Clinical Questionnaires used in this text:- PSO-TARGET QoL Component Grid- DLQI- PASI Scores',\n",
       " 'DLQI (Dermatology Life Quality Index)- PSO-TARGET QoL Component Grid',\n",
       " 'Psoriasis Area and Severity Index (PASI)- Quality of Life component grid- Dermatology Life Quality Index (DLQI)- Psoriasis Treatment Outcome Target (PSO-TARGET) Quality of Life component grid',\n",
       " '1. Dermatology Quality of Life Index (DLQI)2. PSO-TARGET QoL component grid']"
      ]
     },
     "execution_count": 132,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "processed_sections = []\n",
    "for answer in section_answers:\n",
    "    if not answer == 'No validated clinical questionnaires are used in this text.' and not answer == 'None':\n",
    "        temp = answer.replace('\\n', '')\n",
    "        temp1 = temp.replace('The validated clinical questionnaires used in this text are:', '')\n",
    "        temp2 = temp1.replace('The validated clinical questionnaires used in this text:', '')\n",
    "        temp3 = temp2.replace('Validated clinical questionnaires used in this text:', '')\n",
    "        temp4 = temp3.replace('Validated Clinical Questionnaires:-', '')\n",
    "        temp5 = temp4.strip('-')\n",
    "        temp6 = temp5.strip()\n",
    "        processed_sections.append(temp6)\n",
    "    \n",
    "processed_sections"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Validated Clinical Questionnaires:DLQI, PASI, PRO, QoL\n",
      "\n",
      "Validated Clinical Questionnaires:Dermatology Life Quality Index (DLQI)\n",
      "\n",
      "Validated Clinical Questionnaires used in this text:- PSO-TARGET QoL Component Grid- DLQI- PASI Scores\n",
      "\n",
      "DLQI (Dermatology Life Quality Index)- PSO-TARGET QoL Component Grid\n",
      "\n",
      "Psoriasis Area and Severity Index (PASI)- Quality of Life component grid- Dermatology Life Quality Index (DLQI)- Psoriasis Treatment Outcome Target (PSO-TARGET) Quality of Life component grid\n",
      "\n",
      "1. Dermatology Quality of Life Index (DLQI)2. PSO-TARGET QoL component grid\n",
      "\n"
     ]
    }
   ],
   "source": [
    "for answer in processed_sections:\n",
    "    print(answer)\n",
    "    print()\n"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Sections cost 8c"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Chunks"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Cut the document into chunks.\n",
    "1. Start with question\n",
    "2. Keep adding until we get 3500 tokens\n",
    "3. Send the chunk to API"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "question = \"\"\"what validated clinical questionnaires are used in this text?\n",
    "example text: nation', 'EMA', 'European Medicines Agency', 'DLQI', 'Dermatology Life Quality Index', 'EQ-5D', 'European Quality of Life 5-Dimension Questionnaire', 'FCBP', 'Females of childbearing potential', 'FDA', 'Food and Drug Administration'\n",
    "example answer: \n",
    "- EQ-5D, European Quality of Life 5-Dimension Questionnaire\n",
    "- DLQI, Dermatology Life Quality Index\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [],
   "source": [
    "chunks = []\n",
    "page = 0\n",
    "\n",
    "chunk_tokens = 0\n",
    "chunk = question\n",
    "\n",
    "\n",
    "while page < len(text):\n",
    "    page_count = 0\n",
    "    chunk_tokens = 0\n",
    "    chunk = question\n",
    "    while chunk_tokens <= 3500 and page_count < 5 and page < len(text):\n",
    "        chunk += text.iloc[page][2]\n",
    "        chunk_tokens += len(tokenizer(chunk)[0])\n",
    "        page += 1\n",
    "        page_count += 1\n",
    "    chunks.append(chunk)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "for chunk in chunks:\n",
    "    print(chunk)\n",
    "    print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2358"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(tokenizer(chunks[1])[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "myText = 'Protocol 20200060: A PHASE 4, MULTI-CENTER, RANDOMIZED ,DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT OF APREMILAST (CC-10004) ON QUALITY OF LIFE, EFFICACY, AND SAFETY IN SUBJECTS WITH MANIFESTATIONS OF PLAQUE PSORIASIS AND IMPAIRED QUALITY OF LIFE,TITLE PAGE,PROTOCOL SUMMARY,TABLE OF CONTENTS,LIST OF TABLES,Table 1: Study Objectives,Table 2: Study Endpoints,Table 3: Table of Events,Table 4: Abbreviations and Specialist Terms,LIST OF FIGURES,Figure 1: Overall Study Design,1. INTRODUCTION,1.1. Disease Background,1.2. Compound Background,1.3. Rationale,1.3.1. Study Rationale and Purpose,1.3.2. Rationale for the Study Design,2. STUDY OBJECTIVES AND ENDPOINTS,Table 1: Study Objectives,Table 2: Study Endpoints,3. OVERALL STUDY DESIGN,3.1. Study Design,Figure 1: Overall Study Design,3.2. Study Duration for Subjects,3.3. End of Trial,4. STUDY POPULATION,4.1. Number of Subjects,4.2. Inclusion Criteria,4.3. Exclusion Criteria,5. TABLE OF EVENTS,Table 3: Table of Events,6. PROCEDURES,6.1. Screening Period,6.2. Treatment Period,6.2.1. End of Treatment,6.3. Follow-up Period,6.3.1. Post-Treatment Observational Follow-up,6.4. Efficacy Assessments,6.4.1. The Dermatology Life Quality Index (DLQI),6.4.2. Static Physicians Global Assessment (sPGA) of Visible Locations,6.4.3. Scalp Physician Global Assessment (ScPGA),6.4.4. Nail Assessments/Nail Psoriasis Severity Index (NAPSI),6.4.5. Modified static Physicians Global Assessment of Genitalia (Modified sPGA-G),6.4.6. Palmoplantar Psoriasis Physicians Global Assessment (PPPGA),6.4.7. Itch Numeric Rating Scale (NRS),6.4.8. Skin Discomfort/Pain Visual Analog Scale (VAS),6.4.9. Body Surface Area (BSA),6.4.10. Psoriasis Area Severity Index (PASI),6.4.11. Patient Benefit Index (PBI),6.4.12. The European Quality of Life 5-Dimension Questionnaire (EQ-5D),6.4.13. The Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO),6.4.15. Photography,6.5. Safety Assessments,6.5.1. Serum and Urine Pregnancy Tests for Females of Childbearing Potential,6.5.2. Vital Signs, Weight and Waist Circumference,6.5.3. Physical Examination,6.5.4. Psychiatric Evaluation,6.5.5. Severe Diarrhea, Nausea and Vomiting,6.5.6. Clinical Laboratory Evaluations,6.5.7. Tuberculosis,6.5.8. Adverse Events,7. DESCRIPTION OF STUDY TREATMENTS,7.1. Description of Investigational Product(s),7.2. Treatment Administration and Schedule,7.3. Method of Treatment Assignment,7.4. Packaging and Labeling,7.5. Investigational Product Accountability and Disposal,7.6. Investigational Product Compliance,7.7. Overdose,8. CONCOMITANT MEDICATIONS AND PROCEDURES,8.1. Permitted Concomitant Medications and Procedures,8.2. Concomitant Medications Not Recommended,8.3. Prohibited Concomitant Medications and Procedures,8.4. Required Concomitant Medications and Procedures,9. STATISTICAL CONSIDERATIONS,9.1. Overview,9.2. Study Population Definitions,9.3. Sample Size and Power Considerations,9.4. Background and Demographic Characteristics,9.5. Subject Disposition,9.6. Efficacy Analysis,9.6.1. Primary Endpoint,9.6.2. Secondary and Exploratory Efficacy Endpoints,9.6.3. Photography,9.6.5. Multiplicity Adjustment,9.7. Safety Analysis,9.8. Interim Analysis,9.9. Other Topics,9.9.1. Investigational Product Compliance (Tablets),9.9.2. Concomitant Therapy,9.9.3. Steering Committee,10. ADVERSE EVENTS,10.1. Monitoring, Recording and Reporting of Adverse Events,10.2. Evaluation of Adverse Events,10.2.1. Seriousness,10.2.2. Severity / Intensity,10.2.3. Causality,10.2.4. Duration,10.2.5. Action Taken,10.2.6. Outcome,10.3. Abnormal Laboratory Values,10.4. Pregnancy,10.4.1. Females of Childbearing Potential – Collection of Pregnancy Information,10.4.2. Male Subject With Partners Who Become Pregnant,10.4.3. Collection of Lactation Information,10.5. Reporting of Serious Adverse Events,10.5.1. Safety Queries,10.6. Expedited Reporting of Adverse Events,11. DISCONTINUATIONS,11.1. Treatment Discontinuation,11.2. Study Discontinuation,12. EMERGENCY PROCEDURES,12.1. Emergency Contact,12.2. Emergency Identification of Investigational Products,13. REGULATORY CONSIDERATIONS,13.1. Good Clinical Practice,13.2. Investigator Responsibilities,13.3. Subject Information and Informed Consent,13.4. Confidentiality,13.5. Protocol Amendments,13.6. Institutional Review Board/Independent Ethics Committee Review and Approval,13.7. Ongoing Information for Institutional Review Board/Ethics Committee,13.8. Termination of the Study,14. DATA HANDLING AND RECORDKEEPING,14.1. Data/Documents,14.2. Data Management,14.3. Record Retention,15. QUALITY CONTROL AND QUALITY ASSURANCE,15.1. Study Monitoring and Source Data Verification,15.2. Audits and Inspections,15.3. Product Complaint,15.3.1. How to Report a Product Complaint to Amgen,16. PUBLICATIONS,17. REFERENCES,18. APPENDICES,Appendix A: Table of Abbreviations,Table 4: Abbreviations and Specialist Terms,Appendix B: The Dermatology Life Quality Index (DLQI),Appendix C: Static Physicians Global Assessment (sPGA) Of Visible Locations,Appendix D: Scalp Physician Global Assessment (ScPGA),Appendix E: Nail Psoriasis Severity Index (NAPSI),Appendix F: Modified Static Physicians Global Assessment of Genitalia (Modified sPGA-G),Appendix G: Palmoplantar Psoriasis Physicians Global Assessment (PPPGA),Appendix H: Itch Numeric Rating Scale (NRS),Appendix I: Skin Discomfort/Pain Visual Analog Scale (VAS),Appendix J: Psoriasis Area Severity Index (PASI),Appendix K: Patient Needs Questionnaire (PNQ),Appendix L: Patient Benefit Questionnaire (PBQ),Appendix M: European Quality of Life 5-Dimension Questionnaire (EQ-5D),Appendix N: Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO),Appendix O: Waist Circumference Measurement & Body Mass Index,Appendix P: Treatment Schema for Dose Titration at Baseline,Appendix Q: Treatment Schema for Dose Titration at Week 16,Appendix R: Titration Blister Card,Appendix S: Sample Serious Adverse Event Form,Appendix T: Pregnancy Notification Form,Appendix U: Lactation Notification Form,AMENDMENT NO. 3,JUSTIFICATION FOR AMENDMENT,AMENDMENT NO. 2,JUSTIFICATION FOR AMENDMENT,AMENDMENT NO 1.,JUSTIFICATION FOR AMENDMENT'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### GPT3 API\n",
    "1. Run the chunk \n",
    "2. Extract the answers\n",
    "3. Add answers to list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [],
   "source": [
    "answers = []\n",
    "for chunk in chunks:\n",
    "    completion = openai.Completion.create(\n",
    "    model=\"text-davinci-003\",\n",
    "    prompt=f\"extract the validated clinical questionnaires used in this text:{chunk}\",\n",
    "    max_tokens=300,\n",
    "    temperature=0\n",
    "    )\n",
    "    answer = completion[\"choices\"][0][\"text\"]\n",
    "    answers.append(answer)"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Single Use"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "completion = openai.Completion.create(\n",
    "model=\"text-davinci-003\",\n",
    "prompt=f\"extract the validated clinical questionnaires used in this text:{myText}\",\n",
    "max_tokens=300,\n",
    "temperature=0\n",
    ")\n",
    "answer = completion[\"choices\"][0][\"text\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "Validated clinical questionnaires used in this text:\n",
      "\n",
      "-Dermatology Life Quality Index (DLQI)\n",
      "-Static Physicians Global Assessment (sPGA) of Visible Locations\n",
      "-Scalp Physician Global Assessment (ScPGA)\n",
      "-Nail Psoriasis Severity Index (NAPSI)\n",
      "-Modified static Physicians Global Assessment of Genitalia (Modified sPGA-G)\n",
      "-Palmoplantar Psoriasis Physicians Global Assessment (PPPGA)\n",
      "-Itch Numeric Rating Scale (NRS)\n",
      "-Skin Discomfort/Pain Visual Analog Scale (VAS)\n",
      "-Psoriasis Area Severity Index (PASI)\n",
      "-Patient Benefit Index (PBI)\n",
      "-European Quality of Life 5-Dimension Questionnaire (EQ-5D)\n",
      "-Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO)\n"
     ]
    }
   ],
   "source": [
    "print(answer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "answers = ['\\n\\nThe validated clinical questionnaires used in this text are: NIS-PSO-TARGET, Non-Interventional Study Protocol, Dermatology Quality of Life Index (DLQI), PSO-TARGET Quality of Life Component grid.',\n",
    " 'No validated clinical questionnaires are used in this text.',\n",
    " '\\n\\nValidated clinical questionnaires used in this text: PSO-TARGET QoL Component grid, DLQI questionnaire.',\n",
    " '\\n\\nValidated clinical questionnaires used in this text:\\n\\n- NIS-PSO-TARGET\\n- DLQI\\n- PSO-TARGET component grid\\n- PASI Scores',\n",
    " '\\n\\nThe validated clinical questionnaires used in this text are: Psoriasis Area Severity Index (PASI), Dermatology Life Quality Index (DLQI), Patient Benefit Index, and PSO-TARGET QoL Component grid.',\n",
    " '\\n\\nValidated clinical questionnaires used in this text:\\n- NIS-PSO-TARGET\\n- PSO-TARGET Quality of Life Component grid\\n- Dermatology Quality of Life Index (DLQI)',\n",
    " '\\n\\nThe validated clinical questionnaires used in this text are: DLQI (Dermatology Life Quality Index) and the QoL component grid.',\n",
    " '\\n\\nValidated clinical questionnaires used in this text:\\n- Psoriasis Area and Severity Index (PASI)\\n- Dermatology Life Quality Index (DLQI) score\\n- PSO-TARGET QoL component grid',\n",
    " 'No validated clinical questionnaires are used in this text.',\n",
    " '\\n\\nThe validated clinical questionnaires used in this text are: NIS-PSO-TARGET, Non-Interventional Study Protocol, DLQI, PSO-TARGET QoL component grid, and Likert scale.',\n",
    " 'No validated clinical questionnaires are used in this text.',\n",
    " 'No validated clinical questionnaires are used in this text.',\n",
    " 'None',\n",
    " 'No validated clinical questionnaires are used in this text.',\n",
    " '\\n\\nThe validated clinical questionnaires used in this text are: Patient Benefit Index, Dermatology Life Quality Index, and PSO-TARGET Component Grid.']"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Processing\n",
    "1. remove question\n",
    "1. Remove duplicates\n",
    "2. remove answers where no questionnaires were found"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "12"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(answers)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['\\n\\nAnswer: DLQI, EQ-5D, Itch NRS, Skin Discomfort/Pain VAS, PBI, PASI, WPAI: PSO, sPGA, ScPGA, NAPSI, modified sPGA-G, and PPPGA.',\n",
       " '\\n\\nAnswer: EQ-5D, European Quality of Life 5-Dimension Questionnaire; DLQI, Dermatology Life Quality Index; sPGA, Static Physicians Global Assessment; ScPGA, Scalp Physician Global Assessment; NAPSI, Nail Psoriasis Severity Index; Modified sPGA-G, Modified Static Physicians Global Assessment of Genitalia; PPPGA, Palmoplantar Psoriasis Physicians Global Assessment; PASI, Psoriasis Area and Severity Index; BSA, Body Surface Area; EQ-5D, European Quality of Life 5-Dimension Questionnaire; PNQ, Psoriasis Nail Questionnaire; PBQ, Psoriasis Body Questionnaire; WPAI: PSO, Work Productivity and Activity Impairment: Psoriasis; Photography.',\n",
       " '\\n\\nAnswer: DLQI, Dermatology Life Quality Index; EQ-5D, European Quality of Life 5-Dimension; sPGA, Static Physicians Global Assessment; ScPGA, Scalp Physician Global Assessment; NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area Severity Index; Itch NRS, Numeric Rating Scale; VAS, Visual Analog Scale; WPAI:PSO, Work Productivity and Activity Impairment Questionnaire: Psoriasis.',\n",
       " '\\n\\nAnswer: Patient Benefit Index (PBI), Patient Needs Questionnaire (PNQ), Patient Benefit Questionnaire (PBQ), European Quality of Life 5-Dimension Questionnaire (EQ-5D), Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO).',\n",
       " '\\n\\nNo validated clinical questionnaires are used in this text.',\n",
       " '\\n\\nNo validated clinical questionnaires are used in this text.',\n",
       " '\\n\\nNo validated clinical questionnaires are used in this text.',\n",
       " '\\n\\nAnswer: EQ-5D, European Quality of Life 5-Dimension Questionnaire, Pregnancy Notification Form, Pregnancy Questionnaire, Lactation Notification Form, Lactation Questionnaire.',\n",
       " '\\n\\nAnswer: EQ-5D, European Quality of Life 5-Dimension Questionnaire',\n",
       " '\\n\\nAnswer: PBQ, Patient Benefit Questionnaire and EQ-5D, European Quality of Life 5-Dimension Questionnaire.',\n",
       " '\\n\\nAnswer: EQ-5D, European Quality of Life 5-Dimension Questionnaire',\n",
       " '\\n\\nAnswer: EQ-5D, European Quality of Life 5-Dimension Questionnaire']"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "answers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Answer: - DLQI, Dermatology Life Quality Index- EQ-5D, European Quality of Life 5-Dimension Questionnaire- WPAI: PSO, Work Productivity and Activity Impairment Questionnaire: Psoriasis- EQ-5D, European Quality of Life 5-Dimension Questionnaire- sPGA, Static Physician Global Assessment- ScPGA, Scalp Physician Global Assessment- NAPSI, Nail Psoriasis Severity Index- sPGA-G, Modified Static Physician Global Assessment-Genitalia- PPPGA, Palmoplantar Psoriasis Physician Global Assessm',\n",
       " 'Answer:- DLQI, Dermatology Life Quality Index- EQ-5D, European Quality of Life 5-Dimension Questionnaire- PASI, Psoriasis Area and Severity Index- NAPSI, Nail Psoriasis Severity Index- sPGA, Static Physicians Global Assessment- sPGA-G, Modified Static Physicians Global Assessment of Genitalia- PPPGA, Palmoplantar Psoriasis Physicians Global Assessment- Itch NRS, Itch Numeric Rating Scale- VAS, Visual Analogue Scale- BSA, Body Surface Area- PNQ, Psoriasis Nail Questionnaire- PBQ, Psoriasis Body Questionnaire- WPAI: PSO, Work Productivity and Activity Impairment: Psoriasis- Photography',\n",
       " 'Answer: - DLQI, Dermatology Life Quality Index- EQ-5D, European Quality of Life 5-Dimension Questionnaire- PASI, Psoriasis Area Severity Index- Itch NRS, Numeric Rating Scale- VAS, Visual Analog Scale- PPPGA, Palmoplantar Psoriasis Physicians Global Assessment- ScPGA, Scalp Physician Global Assessment- Modified sPGA-G, Modified static Physicians Global Assessment of Genitalia- WPAI:PSO, Work Productivity and Activity Impairment Questionnaire: Psoriasis- PNQ/PBQ, Patient Needs Questionnaire/Patient Benefit Q',\n",
       " 'Answer: - Patient Benefit Index (PBI)- Patient Needs Questionnaire (PNQ)- Patient Benefit Questionnaire (PBQ)- European Quality of Life 5-Dimension Questionnaire (EQ-5D)- Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO)',\n",
       " 'Answer: - DLQI, Dermatology Life Quality Index- EQ-5D, European Quality of Life 5-Dimension Q',\n",
       " 'Answer: - EQ-5D, European Quality of Life 5-Dimension Questionnaire- PBQ, Patient Benefit Q',\n",
       " 'Answer: - EQ-5D, European Quality of Life 5-Dimension Questionnaire- DLQI, Dermatology Life Quality I']"
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "processed = []\n",
    "for answer in answers:\n",
    "    if not answer == 'No validated clinical questionnaires are used in this text.' and not answer == 'None':\n",
    "        temp = answer.replace('\\n', '')\n",
    "        temp1 = temp.replace('The validated clinical questionnaires used in this text are', '')\n",
    "        temp2 = temp1.replace('The validated clinical questionnaires used in this text', '')\n",
    "        temp3 = temp2.replace('Validated clinical questionnaires used in this text', '')\n",
    "        temp4 = temp3.strip(':-').strip('- ')\n",
    "        temp5 = temp4.strip('No validated clinical questionnaires are used in this text.')\n",
    "        processed.append(temp5)\n",
    "    \n",
    "processed = list(filter(None, processed))\n",
    "processed\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Answer: - DLQI, Dermatology Life Quality Index- EQ-5D, European Quality of Life 5-Dimension Questionnaire- WPAI: PSO, Work Productivity and Activity Impairment Questionnaire: Psoriasis- EQ-5D, European Quality of Life 5-Dimension Questionnaire- sPGA, Static Physician Global Assessment- ScPGA, Scalp Physician Global Assessment- NAPSI, Nail Psoriasis Severity Index- sPGA-G, Modified Static Physician Global Assessment-Genitalia- PPPGA, Palmoplantar Psoriasis Physician Global Assessm\n",
      "\n",
      "Answer:- DLQI, Dermatology Life Quality Index- EQ-5D, European Quality of Life 5-Dimension Questionnaire- PASI, Psoriasis Area and Severity Index- NAPSI, Nail Psoriasis Severity Index- sPGA, Static Physicians Global Assessment- sPGA-G, Modified Static Physicians Global Assessment of Genitalia- PPPGA, Palmoplantar Psoriasis Physicians Global Assessment- Itch NRS, Itch Numeric Rating Scale- VAS, Visual Analogue Scale- BSA, Body Surface Area- PNQ, Psoriasis Nail Questionnaire- PBQ, Psoriasis Body Questionnaire- WPAI: PSO, Work Productivity and Activity Impairment: Psoriasis- Photography\n",
      "\n",
      "Answer: - DLQI, Dermatology Life Quality Index- EQ-5D, European Quality of Life 5-Dimension Questionnaire- PASI, Psoriasis Area Severity Index- Itch NRS, Numeric Rating Scale- VAS, Visual Analog Scale- PPPGA, Palmoplantar Psoriasis Physicians Global Assessment- ScPGA, Scalp Physician Global Assessment- Modified sPGA-G, Modified static Physicians Global Assessment of Genitalia- WPAI:PSO, Work Productivity and Activity Impairment Questionnaire: Psoriasis- PNQ/PBQ, Patient Needs Questionnaire/Patient Benefit Q\n",
      "\n",
      "Answer: - Patient Benefit Index (PBI)- Patient Needs Questionnaire (PNQ)- Patient Benefit Questionnaire (PBQ)- European Quality of Life 5-Dimension Questionnaire (EQ-5D)- Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO)\n",
      "\n",
      "Answer: - DLQI, Dermatology Life Quality Index- EQ-5D, European Quality of Life 5-Dimension Q\n",
      "\n",
      "Answer: - EQ-5D, European Quality of Life 5-Dimension Questionnaire- PBQ, Patient Benefit Q\n",
      "\n",
      "Answer: - EQ-5D, European Quality of Life 5-Dimension Questionnaire- DLQI, Dermatology Life Quality I\n",
      "\n"
     ]
    }
   ],
   "source": [
    "for answer in processed:\n",
    "    print(answer)\n",
    "    print()"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "actual cost of Whole protocol 63c"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# PyPDF Extracted csv"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "pypdf1 = pd.read_csv('PyPDF_protocols/trial0027.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "question = \"what validated clinical questionnaires are used in this text?\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "chunks = []\n",
    "page = 0\n",
    "\n",
    "chunk_tokens = 0\n",
    "chunk = question\n",
    "\n",
    "\n",
    "while page < len(pypdf1):\n",
    "    page_count = 0\n",
    "    chunk_tokens = 0\n",
    "    chunk = question\n",
    "    while chunk_tokens <= 3500 and page_count < 5 and page < len(pypdf1):\n",
    "        chunk += pypdf1.iloc[page][2]\n",
    "        chunk_tokens += len(tokenizer(chunk)[0])\n",
    "        page += 1\n",
    "        page_count += 1\n",
    "    chunks.append(chunk)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "answers = []\n",
    "for chunk in chunks:\n",
    "    completion = openai.Completion.create(\n",
    "    model=\"text-davinci-003\",\n",
    "    prompt=f\"extract the validated clinical questionnaires used in this text:{chunk}\",\n",
    "    max_tokens=50,\n",
    "    temperature=0\n",
    "    )\n",
    "    answer = completion[\"choices\"][0][\"text\"]\n",
    "    answers.append(answer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0\n",
      " and their parents/caregivers will complete relevant follow-up HRQOL questionnaires. Validated Clinical Questionnaires used in this text:\n",
      "\n",
      "-Disease-specific HRQOL of peanut-allergic subjects\n",
      "-Dise\n",
      "\n",
      "1\n",
      ".  The proportion of subjects tolerating a single dose of 300 mg (443 mg cumulative), 600 mg (1043 mg cumulative), and 1000 mg (2043 mg cumulative) of peanut protein with no or mild symptoms in the OLFC\n",
      "\n",
      "2\n",
      " 9.1.3 PedsQL Questionnaires .......................................................................................................... .. 72 9.1.4 PedsQL-CF and PedsQL-TF Questionnaires ............................................................................ 72Validated clinical questionnaires used in this text:\n",
      "\n",
      "3\n",
      "Validated clinical questionnaires used in this text:• FAQL-PB Questionnaire• HADS Questionnaire• EQ-5D Questionnaires• Assessments of Control and Confidence• Global Assessments of HRQOL• Assess\n",
      "\n",
      "4\n",
      " compared with 1 of 26 subjects in the placebo group, resulting in a treatment difference of 62% (p < 0.0001 by Fisher exact test).Aimmune Therapeutics, Inc. AR101 ARC009 Protocol Amend 1.0 11 Apr 2018\n",
      "\n",
      "5\n",
      "Validated clinical questionnaires used in this text:\n",
      "\n",
      "• Avery, 2003\n",
      "• Baumert, 2017\n",
      "• Bird, 2018\n",
      "• Bird, 2016\n",
      "• Blumchen, 2010\n",
      "• Dunn-Galvin, 2017\n",
      "•\n",
      "\n",
      "6\n",
      " the RWPC will continue AR101 daily at 300 mg/day and will have the option to consent for a second RWPC approximately 4 weeks after the first RWPC.Validated clinical questionnaires used in this text:\n",
      "\n",
      "-Disease\n",
      "\n",
      "7\n",
      "  Use of oral corticosteroids within the past 3 months  Hospitalization for asthma within the past 12 months  Emergency department visit for asthma within the past 6 months  Uncontrolled asthma symptoms (eg,\n",
      "\n",
      "8\n",
      " AR101-treated subject at early discontinuation/study exit) [1] 11 Qualitative exit interview (for AR101-treated subject aged 4-12 years at early discontinuation/study exit) [2] Validated clinical questionnaires used\n",
      "\n",
      "9\n",
      " The maintenance period will begin when subjects are able to tolerate 300 mg/day for 2 weeks. Subjects will receive study product to continue daily dosing at home with 300 mg/day for a total of 4 weeks. Subjects will return to the study site\n",
      "\n",
      "10\n",
      "Validated clinical questionnaires used in this text: - EQ-5D - Food Allergy Quality of Life Questionnaire (FAQLQ) - Food Allergy Independent Measure (FAIM)\n",
      "\n",
      "11\n",
      "Validated clinical questionnaires used in this text: EQ-5D, European Quality of Life 5-Dimensions health questionnaire; FAIM, Food Allergy Independent Measure; FAQLQ, Food Allergy Quality of Life Questionnaire; Pediatric\n",
      "\n",
      "12\n",
      " Table 8: Criteria for Serious Adverse Events Criteria Examples  Death  Life-threatening event  Hospitalization or prolongation of existing hospitalization  Persistent or significant disability/incapacity\n",
      "\n",
      "13\n",
      " The assessment of anaphylaxis should follow the European Academy of Allergy and Clinical Immunology (EAACI) guidelines ( Table 10 ; adapted from Muraro, 2007). Validated clinical questionnaires used in this text:\n",
      "\n",
      "CoF\n",
      "\n",
      "14\n",
      "NoNoYesYesNoValidated clinical questionnaires used in this text: None\n",
      "\n",
      "15\n",
      " symptoms, reduce the dose level by 1 or 2 dose levels and continue dosing at the reduced level for at least 2 weeks before attempting dose re-escalation.No validated clinical questionnaires are used in this text.\n",
      "\n",
      "16\n",
      " Table 17: Procedures for Missed Consecutive Doses of Study Product During Up-Dosing and Maintenance Missed Doses Action 1-2 consecutive doses Resume dosing at the previous dose level under medical supervision at the study site, and\n",
      "\n",
      "17\n",
      " addition, the safety of AR101 in pregnant women has not been established. Therefore, women of childbearing potential must use an acceptable method of contraception during the study and for at least 6 months after the last dose of study product ( Section 7.1\n",
      "\n",
      "18\n",
      " termination, and the outcome will be reported to the sponsor. Overdose: Overdose of study product must be reported to the sponsor on an overdose report form.Aimmune Therapeutics, No validated clinical questionnaires are used in this text.\n",
      "\n",
      "19\n",
      " restrictions and risk of accidental exposure scored as separate domains) and consists of 25 items ( Flokstra-de Blok, 2009 ). Each item contains response options from 0 (no impact) to 6 (extreme impact) and is scored on a 7\n",
      "\n",
      "20\n",
      " The Asthma Control Test (ACT) will be administered to subjects aged ≥ 12 years at screening and at each visit. The ACT is a 5-item questionnaire that assesses asthma control over the past 4 weeks. The ACT score ranges from 5 to\n",
      "\n",
      "21\n",
      " of care alone who complete the exit visit (ie, do not discontinue early). The safety population will be defined as all subjects who receive any part of 1 dose of study product.Validated clinical questionnaires used in this text:Asthma Control\n",
      "\n",
      "22\n",
      " maximum severity of symptoms at the OLFC and by treatment group. The Cochran-Mantel-Haenszel statistics with equally spaced scores (row mean score differences statistic) stratified by country will be used to test for a treatment difference.\n",
      "\n",
      "23\n",
      " EC and regulatory authorities as required by local regulations.Validated clinical questionnaires used in this text: None\n",
      "\n",
      "24\n",
      " to the investigator. The investigator must immediately inform all subjects of the study termination and must provide the subjects with the appropriate medical care.Validated clinical questionnaires used in this text: None\n",
      "\n",
      "25\n",
      "Noone S, Cohen BL, Muñoz-Furlong A, Sicherer SH. Development of a questionnaire to measure quality of life in families with a child with food allergy. J Allergy Clin Immunol. 2004;114(5\n",
      "\n",
      "26\n",
      " The study physician will be responsible for the safety of the subject during the OLFC. The study physician will be present during the entire OLFC and will be responsible for the safety of the subject during the OLFC. The study physician will be responsible for\n",
      "\n",
      "27\n",
      " Administer the OLFC Dose Administer the OLFC dose as follows:  Instruct the subject to swallow the dose in one mouthful.  Observe the subject for at least 20 minutes after the dose is administered.Val\n",
      "\n",
      "28\n",
      "No validated clinical questionnaires are used in this text.\n",
      "\n",
      "29\n",
      " Table 2: Definitions of Allergic Symptom Severity Symptom Severity Definition Mild Symptoms that do not interfere with normal activity and do not require treatment. Moderate Symptoms that interfere with normal activity and require treatment. Severe Symptoms that require intensive\n",
      "\n",
      "30\n",
      "No validated clinical questionnaires are used in this text.\n",
      "\n",
      "31\n",
      "Validated clinical questionnaires used in this text include: EQ-5D, FAQL-PB, HADS, FAQLQ, FAIM, PEESS v2.0, PEFR, ACT/C-ACT, SCORAD\n",
      "\n",
      "32\n",
      " [23] For female subject aged ≥ 12 years.Validated clinical questionnaires used in this text:EQ-5DFAQL-PBHADSFAMLQ, FAIMTSQM-9Bespoke global assessment of\n",
      "\n",
      "33\n",
      "Validated clinical questionnaires used in this text: \n",
      "\n",
      "-EQ-5D \n",
      "-EQ-5D-5L \n",
      "-EQ-5D-Y \n",
      "-FAQL-PB \n",
      "-\n",
      "\n",
      "34\n",
      "\n",
      "\n",
      "The validated clinical questionnaire used in this text is the PEESS v2.0 questionnaire.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "for index, answer in enumerate(answers):\n",
    "    print(index)\n",
    "    print(answer)\n",
    "    print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.1"
  },
  "orig_nbformat": 4,
  "vscode": {
   "interpreter": {
    "hash": "9464ac5cfb2010fde3ae7f0d3430beeb41c2cace6af57bfda8f8d5420c56c15e"
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
